25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

0OT (Ocular Therapeutix Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Ocular Therapeutix Inc together

I guess you are interested in Ocular Therapeutix Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Ocular Therapeutix Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Ocular Therapeutix Inc’s Price Targets

I'm going to help you getting a better view of Ocular Therapeutix Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Ocular Therapeutix Inc

I send you an email if I find something interesting about Ocular Therapeutix Inc.

1. Quick Overview

1.1. Quick analysis of Ocular Therapeutix Inc (30 sec.)










1.2. What can you expect buying and holding a share of Ocular Therapeutix Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€1.79
Expected worth in 1 year
€3.06
How sure are you?
40.9%

+ What do you gain per year?

Total Gains per Share
€1.27
Return On Investment
19.3%

For what price can you sell your share?

Current Price per Share
€6.58
Expected price per share
€3.831 - €8.682
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Ocular Therapeutix Inc (5 min.)




Live pricePrice per Share (EOD)
€6.58
Intrinsic Value Per Share
€-10.21 - €-12.07
Total Value Per Share
€-8.42 - €-10.28

2.2. Growth of Ocular Therapeutix Inc (5 min.)




Is Ocular Therapeutix Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$315.3m$27.9m$335.3m92.3%

How much money is Ocular Therapeutix Inc making?

Current yearPrevious yearGrowGrow %
Making money-$48.3m-$20.1m-$28.1m-58.3%
Net Profit Margin-306.3%-140.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Ocular Therapeutix Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#229 / 890

Most Revenue
#254 / 890

Most Profit
#782 / 890

Most Efficient
#620 / 890
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Ocular Therapeutix Inc?

Welcome investor! Ocular Therapeutix Inc's management wants to use your money to grow the business. In return you get a share of Ocular Therapeutix Inc.

First you should know what it really means to hold a share of Ocular Therapeutix Inc. And how you can make/lose money.

Speculation

The Price per Share of Ocular Therapeutix Inc is €6.582. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ocular Therapeutix Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ocular Therapeutix Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €1.79. Based on the TTM, the Book Value Change Per Share is €0.32 per quarter. Based on the YOY, the Book Value Change Per Share is €0.08 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ocular Therapeutix Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps-0.30-4.6%-0.30-4.6%-0.13-1.9%-0.18-2.7%-0.16-2.4%-0.16-2.4%
Usd Book Value Change Per Share-0.23-3.5%0.355.4%0.091.3%0.121.8%0.101.5%0.091.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.23-3.5%0.355.4%0.091.3%0.121.8%0.101.5%0.091.4%
Usd Price Per Share8.85-8.47-4.68-5.78-7.59-7.23-
Price to Earnings Ratio-7.27--7.21--68.69--28.61--9.18--8.94-
Price-to-Total Gains Ratio-38.38--31.12--10.62--32.59-46.96-42.77-
Price to Book Ratio4.46-3.75-108.68-41.57-25.01-16.67-
Price-to-Total Gains Ratio-38.38--31.12--10.62--32.59-46.96-42.77-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.30602
Number of shares136
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.350.10
Usd Total Gains Per Share0.350.10
Gains per Quarter (136 shares)47.9413.64
Gains per Year (136 shares)191.7554.56
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1019218205545
203843740109100
305755660164155
407677580218210
509599500273265
60115111420327320
70134213340382375
80153415260436430
90172617180491485
100191819100546540

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%2.020.00.09.1%2.020.00.09.1%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%8.012.00.040.0%9.013.00.040.9%9.013.00.040.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%8.012.00.040.0%9.013.00.040.9%9.013.00.040.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Ocular Therapeutix Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.2080.318-165%0.079-363%0.107-294%0.090-330%0.081-356%
Book Value Per Share--1.7872.058-13%0.158+1028%0.846+111%0.623+187%0.568+215%
Current Ratio--10.66415.425-31%4.351+145%8.470+26%7.984+34%7.773+37%
Debt To Asset Ratio--0.3110.277+13%0.872-64%0.605-49%0.679-54%0.705-56%
Debt To Equity Ratio--0.4520.384+18%18.096-98%6.879-93%5.534-92%5.342-92%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--1139581196.1001089569097.725+5%545072635.575+109%711450979.475+60%970801791.105+17%923566167.318+23%
Eps---0.274-0.2740%-0.114-58%-0.163-41%-0.144-48%-0.142-48%
Ev To Sales Ratio--18.51319.105-3%10.461+77%13.496+37%35.910-48%41.458-55%
Free Cash Flow Per Share---0.225-0.193-14%-0.108-52%-0.130-42%-0.112-50%-0.112-50%
Free Cash Flow To Equity Per Share---0.1990.278-172%0.132-250%0.108-285%0.096-308%0.096-308%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---12.070----------
Intrinsic Value_10Y_min---10.207----------
Intrinsic Value_1Y_max---0.621----------
Intrinsic Value_1Y_min---0.610----------
Intrinsic Value_3Y_max---2.315----------
Intrinsic Value_3Y_min---2.201----------
Intrinsic Value_5Y_max---4.549----------
Intrinsic Value_5Y_min---4.183----------
Market Cap1046682804.000-21%1268041428.0001213735415.000+4%669800664.000+89%827550488.000+53%1086899467.800+17%1035652459.818+22%
Net Profit Margin---2.833-3.063+8%-1.409-50%-1.958-31%-3.456+22%-4.696+66%
Operating Margin----0%-0.7600%-0.7660%-1.9910%-3.1870%
Operating Ratio--4.0333.772+7%2.508+61%2.969+36%3.713+9%5.228-23%
Pb Ratio3.684-21%4.4633.746+19%108.678-96%41.573-89%25.015-82%16.666-73%
Pe Ratio-6.003+17%-7.272-7.212-1%-68.690+845%-28.607+293%-9.180+26%-8.939+23%
Price Per Share6.582-21%7.9747.633+4%4.212+89%5.204+53%6.835+17%6.513+22%
Price To Free Cash Flow Ratio-7.329+17%-8.879-10.012+13%-10.793+22%-10.630+20%-19.737+122%-17.943+102%
Price To Total Gains Ratio-31.677+17%-38.376-31.121-19%-10.616-72%-32.586-15%46.956-182%42.769-190%
Quick Ratio--0.7830.929-16%0.744+5%0.817-4%0.703+11%0.654+20%
Return On Assets---0.106-0.096-9%-0.131+24%-0.112+6%-0.123+16%-0.136+29%
Return On Equity---0.153-0.133-13%-2.552+1563%-1.012+560%-1.010+558%-0.993+547%
Total Gains Per Share---0.2080.318-165%0.079-363%0.107-294%0.090-330%0.081-356%
Usd Book Value--315343684.656363260386.739-13%27945472.055+1028%149335767.331+111%109883840.116+187%100243081.575+215%
Usd Book Value Change Per Share---0.2310.352-165%0.088-363%0.119-294%0.100-330%0.090-356%
Usd Book Value Per Share--1.9832.284-13%0.176+1028%0.939+111%0.691+187%0.630+215%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--1264935127.6711209421698.475+5%605030625.488+109%789710587.217+60%1077589988.127+17%1025158445.723+23%
Usd Eps---0.304-0.3040%-0.127-58%-0.181-41%-0.160-48%-0.158-48%
Usd Free Cash Flow---39630960.369-33991216.009-14%-19080230.920-52%-22966977.033-42%-19837130.163-50%-18033754.694-54%
Usd Free Cash Flow Per Share---0.249-0.214-14%-0.120-52%-0.144-42%-0.125-50%-0.125-50%
Usd Free Cash Flow To Equity Per Share---0.2210.308-172%0.147-250%0.119-285%0.106-308%0.106-308%
Usd Market Cap1161817912.440-21%1407525985.0801347246310.650+4%743478737.040+89%918581041.680+53%1206458409.258+17%1149574230.398+22%
Usd Price Per Share7.306-21%8.8518.472+4%4.675+89%5.776+53%7.587+17%7.229+22%
Usd Profit---48387951.612-48376451.6240%-20183979.816-58%-28773304.560-41%-25373424.627-48%-25102883.988-48%
Usd Revenue--17081982.91815930484.070+7%14610485.390+17%14471485.529+18%11729088.271+46%10803034.652+58%
Usd Total Gains Per Share---0.2310.352-165%0.088-363%0.119-294%0.100-330%0.090-356%
 EOD+3 -5MRQTTM+8 -27YOY+17 -183Y+16 -195Y+17 -1810Y+18 -17

3.3 Fundamental Score

Let's check the fundamental score of Ocular Therapeutix Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.003
Price to Book Ratio (EOD)Between0-13.684
Net Profit Margin (MRQ)Greater than0-2.833
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.783
Current Ratio (MRQ)Greater than110.664
Debt to Asset Ratio (MRQ)Less than10.311
Debt to Equity Ratio (MRQ)Less than10.452
Return on Equity (MRQ)Greater than0.15-0.153
Return on Assets (MRQ)Greater than0.05-0.106
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Ocular Therapeutix Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.319
Ma 20Greater thanMa 506.552
Ma 50Greater thanMa 1006.639
Ma 100Greater thanMa 2007.172
OpenGreater thanClose6.556
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Fundamental data was last updated by Penke on 2025-04-30 14:52:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Ocular Therapeutix Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Ocular Therapeutix Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -283.3%Β means thatΒ €-2.83 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ocular Therapeutix Inc:

  • The MRQ is -283.3%. The company is making a huge loss. -2
  • The TTM is -306.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-283.3%TTM-306.3%+23.0%
TTM-306.3%YOY-140.9%-165.3%
TTM-306.3%5Y-345.6%+39.3%
5Y-345.6%10Y-469.6%+124.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-283.3%-88.9%-194.4%
TTM-306.3%-182.1%-124.2%
YOY-140.9%-195.7%+54.8%
3Y-195.8%-244.6%+48.8%
5Y-345.6%-350.0%+4.4%
10Y-469.6%-491.0%+21.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Ocular Therapeutix Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Ocular Therapeutix Inc to theΒ Biotechnology industry mean.
  • -10.6% Return on Assets means thatΒ Ocular Therapeutix Inc generatedΒ €-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ocular Therapeutix Inc:

  • The MRQ is -10.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.6%TTM-9.6%-0.9%
TTM-9.6%YOY-13.1%+3.5%
TTM-9.6%5Y-12.3%+2.7%
5Y-12.3%10Y-13.6%+1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.6%-11.3%+0.7%
TTM-9.6%-11.5%+1.9%
YOY-13.1%-11.5%-1.6%
3Y-11.2%-11.9%+0.7%
5Y-12.3%-12.5%+0.2%
10Y-13.6%-14.1%+0.5%
4.3.1.3. Return on Equity

Shows how efficient Ocular Therapeutix Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Ocular Therapeutix Inc to theΒ Biotechnology industry mean.
  • -15.3% Return on Equity means Ocular Therapeutix Inc generated €-0.15Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ocular Therapeutix Inc:

  • The MRQ is -15.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -13.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.3%TTM-13.3%-2.0%
TTM-13.3%YOY-255.2%+241.9%
TTM-13.3%5Y-101.0%+87.7%
5Y-101.0%10Y-99.3%-1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.3%-14.5%-0.8%
TTM-13.3%-15.1%+1.8%
YOY-255.2%-15.0%-240.2%
3Y-101.2%-17.5%-83.7%
5Y-101.0%-18.0%-83.0%
10Y-99.3%-19.9%-79.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Ocular Therapeutix Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Ocular Therapeutix Inc is operatingΒ .

  • Measures how much profit Ocular Therapeutix Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Ocular Therapeutix Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ocular Therapeutix Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-76.0%+76.0%
TTM-5Y-199.1%+199.1%
5Y-199.1%10Y-318.7%+119.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--177.6%+177.6%
TTM--289.9%+289.9%
YOY-76.0%-208.5%+132.5%
3Y-76.6%-248.9%+172.3%
5Y-199.1%-360.9%+161.8%
10Y-318.7%-475.6%+156.9%
4.3.2.2. Operating Ratio

Measures how efficient Ocular Therapeutix Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 4.03 means that the operating costs are €4.03 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 4.033. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.772. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.033TTM3.772+0.261
TTM3.772YOY2.508+1.265
TTM3.7725Y3.713+0.059
5Y3.71310Y5.228-1.515
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0332.175+1.858
TTM3.7723.048+0.724
YOY2.5083.051-0.543
3Y2.9693.656-0.687
5Y3.7134.839-1.126
10Y5.2286.533-1.305
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Ocular Therapeutix Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Ocular Therapeutix Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 10.66Β means the company has €10.66 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 10.664. The company is very able to pay all its short-term debts. +2
  • The TTM is 15.425. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.664TTM15.425-4.762
TTM15.425YOY4.351+11.075
TTM15.4255Y7.984+7.441
5Y7.98410Y7.773+0.211
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.6643.588+7.076
TTM15.4253.932+11.493
YOY4.3514.286+0.065
3Y8.4704.809+3.661
5Y7.9845.816+2.168
10Y7.7736.204+1.569
4.4.3.2. Quick Ratio

Measures if Ocular Therapeutix Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Ocular Therapeutix Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.78Β means the company can pay off €0.78 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 0.783. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.929. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.783TTM0.929-0.146
TTM0.929YOY0.744+0.185
TTM0.9295Y0.703+0.226
5Y0.70310Y0.654+0.050
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7832.845-2.062
TTM0.9293.439-2.510
YOY0.7444.128-3.384
3Y0.8174.673-3.856
5Y0.7035.938-5.235
10Y0.6546.556-5.902
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Ocular Therapeutix Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Ocular Therapeutix IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Ocular Therapeutix Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.31Β means that Ocular Therapeutix Inc assets areΒ financed with 31.1% credit (debt) and the remaining percentage (100% - 31.1%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 0.311. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.277. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.311TTM0.277+0.035
TTM0.277YOY0.872-0.596
TTM0.2775Y0.679-0.403
5Y0.67910Y0.705-0.025
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3110.342-0.031
TTM0.2770.342-0.065
YOY0.8720.330+0.542
3Y0.6050.329+0.276
5Y0.6790.359+0.320
10Y0.7050.382+0.323
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Ocular Therapeutix Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Ocular Therapeutix Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 45.2% means that company has €0.45 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 0.452. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.384. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.452TTM0.384+0.068
TTM0.384YOY18.096-17.712
TTM0.3845Y5.534-5.150
5Y5.53410Y5.342+0.192
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4520.410+0.042
TTM0.3840.427-0.043
YOY18.0960.408+17.688
3Y6.8790.428+6.451
5Y5.5340.447+5.087
10Y5.3420.494+4.848
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Ocular Therapeutix Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Ocular Therapeutix Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -7.27 means the investor is paying €-7.27Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ocular Therapeutix Inc:

  • The EOD is -6.003. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.272. Based on the earnings, the company is expensive. -2
  • The TTM is -7.212. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.003MRQ-7.272+1.269
MRQ-7.272TTM-7.212-0.060
TTM-7.212YOY-68.690+61.477
TTM-7.2125Y-9.180+1.967
5Y-9.18010Y-8.939-0.241
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.003-1.735-4.268
MRQ-7.272-2.410-4.862
TTM-7.212-3.010-4.202
YOY-68.690-3.337-65.353
3Y-28.607-4.007-24.600
5Y-9.180-6.317-2.863
10Y-8.939-6.805-2.134
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ocular Therapeutix Inc:

  • The EOD is -7.329. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.879. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.012. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.329MRQ-8.879+1.550
MRQ-8.879TTM-10.012+1.134
TTM-10.012YOY-10.793+0.781
TTM-10.0125Y-19.737+9.725
5Y-19.73710Y-17.943-1.794
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.329-2.387-4.942
MRQ-8.879-3.244-5.635
TTM-10.012-3.963-6.049
YOY-10.793-4.345-6.448
3Y-10.630-5.424-5.206
5Y-19.737-8.416-11.321
10Y-17.943-9.392-8.551
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Ocular Therapeutix Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 4.46 means the investor is paying €4.46Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Ocular Therapeutix Inc:

  • The EOD is 3.684. Based on the equity, the company is fair priced.
  • The MRQ is 4.463. Based on the equity, the company is fair priced.
  • The TTM is 3.746. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.684MRQ4.463-0.779
MRQ4.463TTM3.746+0.718
TTM3.746YOY108.678-104.932
TTM3.7465Y25.015-21.269
5Y25.01510Y16.666+8.349
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.6841.723+1.961
MRQ4.4632.114+2.349
TTM3.7462.377+1.369
YOY108.6782.474+106.204
3Y41.5732.757+38.816
5Y25.0153.696+21.319
10Y16.6664.294+12.372
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets457,935
Total Liabilities142,591
Total Stockholder Equity315,344
 As reported
Total Liabilities 142,591
Total Stockholder Equity+ 315,344
Total Assets = 457,935

Assets

Total Assets457,935
Total Current Assets440,987
Long-term Assets16,948
Total Current Assets
Cash And Cash Equivalents 392,102
Net Receivables 32,388
Inventory 3,040
Other Current Assets 13,457
Total Current Assets  (as reported)440,987
Total Current Assets  (calculated)440,987
+/-0
Long-term Assets
Property Plant Equipment 15,334
Long-term Assets Other 1,614
Long-term Assets  (as reported)16,948
Long-term Assets  (calculated)16,948
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities41,354
Long-term Liabilities101,237
Total Stockholder Equity315,344
Total Current Liabilities
Accounts payable 4,176
Total Current Liabilities  (as reported)41,354
Total Current Liabilities  (calculated)4,176
+/- 37,178
Long-term Liabilities
Long term Debt 68,505
Capital Lease Obligations Min Short Term Debt7,278
Long-term Liabilities Other 141
Long-term Liabilities  (as reported)101,237
Long-term Liabilities  (calculated)75,924
+/- 25,313
Total Stockholder Equity
Total Stockholder Equity (as reported)315,344
Total Stockholder Equity (calculated)0
+/- 315,344
Other
Capital Stock16
Common Stock Shares Outstanding 157,749
Net Invested Capital 383,849
Net Working Capital 399,633
Property Plant and Equipment Gross 38,966



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
88,710
78,740
72,857
107,260
98,219
261,863
243,040
230,707
217,739
204,887
187,622
173,071
158,579
149,289
128,573
122,558
162,384
252,060
538,947
517,091
490,369
457,935
457,935490,369517,091538,947252,060162,384122,558128,573149,289158,579173,071187,622204,887217,739230,707243,040261,86398,219107,26072,85778,74088,710
   > Total Current Assets 
69,636
60,170
55,153
90,293
81,903
246,160
228,132
216,523
203,932
191,300
174,652
160,322
145,615
129,627
107,162
100,712
141,258
232,235
519,824
498,585
473,011
440,987
440,987473,011498,585519,824232,235141,258100,712107,162129,627145,615160,322174,652191,300203,932216,523228,132246,16081,90390,29355,15360,17069,636
       Cash And Cash Equivalents 
65,414
54,437
48,152
84,294
70,642
228,057
209,378
191,860
179,281
164,164
145,417
134,539
120,950
102,300
79,026
66,606
110,550
195,807
482,888
459,690
427,220
392,102
392,102427,220459,690482,888195,807110,55066,60679,026102,300120,950134,539145,417164,164179,281191,860209,378228,05770,64284,29448,15254,43765,414
       Net Receivables 
1,114
2,548
3,429
2,874
7,779
12,252
13,631
18,734
19,552
21,135
23,207
20,482
19,802
21,325
21,124
27,309
23,589
26,179
26,546
30,232
30,235
32,388
32,38830,23530,23226,54626,17923,58927,30921,12421,32519,80220,48223,20721,13519,55218,73413,63112,2527,7792,8743,4292,5481,114
       Inventory 
895
954
1,107
1,067
1,154
1,201
1,123
1,112
1,222
1,250
1,358
1,500
1,545
1,974
2,266
2,204
2,257
2,305
2,574
2,547
2,405
3,040
3,0402,4052,5472,5742,3052,2572,2042,2661,9741,5451,5001,3581,2501,2221,1121,1231,2011,1541,0671,107954895
   > Long-term Assets 
19,074
18,570
17,704
16,967
16,316
15,703
14,908
14,184
13,807
13,587
12,970
12,749
12,964
19,662
21,411
21,846
21,126
19,825
19,123
18,506
17,358
16,948
16,94817,35818,50619,12319,82521,12621,84621,41119,66212,96412,74912,97013,58713,80714,18414,90815,70316,31616,96717,70418,57019,074
       Property Plant Equipment 
17,310
16,806
15,940
15,203
14,552
13,939
13,144
12,420
12,043
11,823
11,206
10,985
11,200
17,898
19,647
20,082
19,362
18,211
17,509
16,892
15,744
15,334
15,33415,74416,89217,50918,21119,36220,08219,64717,89811,20010,98511,20611,82312,04312,42013,14413,93914,55215,20315,94016,80617,310
       Other Assets 
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
0
0
0
0
0
0
0000001,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,764
> Total Liabilities 
77,409
82,370
83,516
101,916
102,345
185,768
159,632
150,460
130,399
116,888
107,827
107,268
112,350
113,910
118,862
119,471
154,531
160,929
130,964
139,396
138,348
142,591
142,591138,348139,396130,964160,929154,531119,471118,862113,910112,350107,268107,827116,888130,399150,460159,632185,768102,345101,91683,51682,37077,409
   > Total Current Liabilities 
11,005
12,029
11,112
13,803
22,906
26,664
27,437
21,550
25,158
26,337
23,960
26,113
29,269
31,395
29,715
32,357
35,066
34,896
24,298
29,972
36,359
41,354
41,35436,35929,97224,29834,89635,06632,35729,71531,39529,26926,11323,96026,33725,15821,55027,43726,66422,90613,80311,11212,02911,005
       Short Long Term Debt 
0
0
2,074
4,146
6,206
8,290
8,290
0
0
0
0
0
0
0
0
2,083
0
0
0
0
0
0
0000002,083000000008,2908,2906,2064,1462,07400
       Accounts payable 
3,461
3,268
2,839
2,650
3,238
2,709
4,152
3,881
4,246
4,592
3,420
3,703
5,308
5,123
5,441
3,572
3,984
4,389
6,453
3,689
4,001
4,176
4,1764,0013,6896,4534,3893,9843,5725,4415,1235,3083,7033,4204,5924,2463,8814,1522,7093,2382,6502,8393,2683,461
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
1,208
1,189
603
576
463
391
0
0
0
0
0
0
0000003914635766031,1891,2080000000000
   > Long-term Liabilities 
66,404
70,341
72,404
88,113
79,439
159,104
132,195
128,910
105,241
90,551
83,867
81,155
83,081
82,515
89,147
87,114
119,465
126,033
106,666
109,424
101,989
101,237
101,237101,989109,424106,666126,033119,46587,11489,14782,51583,08181,15583,86790,551105,241128,910132,195159,10479,43988,11372,40470,34166,404
       Long term Debt 
48,098
49,312
48,286
47,322
42,766
41,243
39,729
50,239
50,822
51,435
52,058
52,695
53,344
54,006
54,679
53,284
73,889
74,925
66,456
67,132
67,815
68,505
68,50567,81567,13266,45674,92573,88953,28454,67954,00653,34452,69552,05851,43550,82250,23939,72941,24342,76647,32248,28649,31248,098
       Capital Lease Obligations Min Short Term Debt
10,279
10,031
9,771
9,494
9,206
8,906
8,590
8,257
7,909
7,548
7,168
6,770
6,354
10,277
9,932
9,402
9,129
8,464
7,949
7,756
7,309
7,278
7,2787,3097,7567,9498,4649,1299,4029,93210,2776,3546,7707,1687,5487,9098,2578,5908,9069,2069,4949,77110,03110,279
       Other Liabilities 
9,100
12,124
15,528
32,535
28,764
110,313
85,297
71,901
48,064
33,192
26,337
23,461
25,127
19,831
26,354
26,141
0
0
0
0
0
0
00000026,14126,35419,83125,12723,46126,33733,19248,06471,90185,297110,31328,76432,53515,52812,1249,100
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
93
100
104
106
108
111
114
117
141
141117114111108106104100930000000000000
> Total Stockholder Equity
11,301
-3,630
-10,659
5,344
-4,126
76,095
83,408
80,247
87,340
87,999
79,795
65,803
46,229
35,379
9,711
3,087
7,853
91,131
407,983
377,695
352,021
315,344
315,344352,021377,695407,98391,1317,8533,0879,71135,37946,22965,80379,79587,99987,34080,24783,40876,095-4,1265,344-10,659-3,63011,301
   Common Stock
5
5
5
6
6
8
8
8
8
8
8
8
8
8
8
8
0
0
0
0
0
0
0000008888888888866555
   Retained Earnings Total Equity0000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 0000000000000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue63,723
Cost of Revenue-5,626
Gross Profit58,09758,097
 
Operating Income (+$)
Gross Profit58,097
Operating Expense-235,504
Operating Income-171,781-177,407
 
Operating Expense (+$)
Research Development127,635
Selling General Administrative102,243
Selling And Marketing Expenses-
Operating Expense235,504229,878
 
Net Interest Income (+$)
Interest Income20,282
Interest Expense-13,577
Other Finance Cost-0
Net Interest Income6,705
 
Pretax Income (+$)
Operating Income-171,781
Net Interest Income6,705
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-193,506-143,351
EBIT - interestExpense = -13,577
-193,506
-179,929
Interest Expense13,577
Earnings Before Interest and Taxes (EBIT)--179,929
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-193,506
Tax Provision--
Net Income From Continuing Ops-193,506-193,506
Net Income-193,506
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-28,430-6,705
 

Technical Analysis of Ocular Therapeutix Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ocular Therapeutix Inc. The general trend of Ocular Therapeutix Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ocular Therapeutix Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Ocular Therapeutix Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ocular Therapeutix Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 7.868 < 7.974 < 8.682.

The bearish price targets are: 5.412 > 4.502 > 3.831.

Know someone who trades $0OT? Share this with them.πŸ‘‡

Ocular Therapeutix Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ocular Therapeutix Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ocular Therapeutix Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ocular Therapeutix Inc. The current macd is 0.00410966.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ocular Therapeutix Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Ocular Therapeutix Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Ocular Therapeutix Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Ocular Therapeutix Inc Daily Moving Average Convergence/Divergence (MACD) ChartOcular Therapeutix Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ocular Therapeutix Inc. The current adx is 15.67.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Ocular Therapeutix Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Ocular Therapeutix Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ocular Therapeutix Inc. The current sar is 7.5880128.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Ocular Therapeutix Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ocular Therapeutix Inc. The current rsi is 49.32. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Ocular Therapeutix Inc Daily Relative Strength Index (RSI) ChartOcular Therapeutix Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ocular Therapeutix Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Ocular Therapeutix Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Ocular Therapeutix Inc Daily Stochastic Oscillator ChartOcular Therapeutix Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ocular Therapeutix Inc. The current cci is 1.73504797.

Ocular Therapeutix Inc Daily Commodity Channel Index (CCI) ChartOcular Therapeutix Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ocular Therapeutix Inc. The current cmo is -2.08841634.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Ocular Therapeutix Inc Daily Chande Momentum Oscillator (CMO) ChartOcular Therapeutix Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ocular Therapeutix Inc. The current willr is -66.82867558.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Ocular Therapeutix Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Ocular Therapeutix Inc Daily Williams %R ChartOcular Therapeutix Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Ocular Therapeutix Inc.

Ocular Therapeutix Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ocular Therapeutix Inc. The current atr is 0.33946559.

Ocular Therapeutix Inc Daily Average True Range (ATR) ChartOcular Therapeutix Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ocular Therapeutix Inc. The current obv is -105,586.

Ocular Therapeutix Inc Daily On-Balance Volume (OBV) ChartOcular Therapeutix Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ocular Therapeutix Inc. The current mfi is 61.31.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Ocular Therapeutix Inc Daily Money Flow Index (MFI) ChartOcular Therapeutix Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ocular Therapeutix Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-16 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-03 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-10 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-13 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-14 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-20 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-22 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-29 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-03 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-04 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-06 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-10 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-11 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-17 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-24 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-26 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-03 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-04 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-06 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-07 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-12 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-17 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-18 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-19 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-27 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-15 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-29 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-02 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-06 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-07 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-08 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-09 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Ocular Therapeutix Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ocular Therapeutix Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.319
Ma 20Greater thanMa 506.552
Ma 50Greater thanMa 1006.639
Ma 100Greater thanMa 2007.172
OpenGreater thanClose6.556
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Ocular Therapeutix Inc with someone you think should read this too:
  • Are you bullish or bearish on Ocular Therapeutix Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ocular Therapeutix Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ocular Therapeutix Inc

I send you an email if I find something interesting about Ocular Therapeutix Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Ocular Therapeutix Inc.

Receive notifications about Ocular Therapeutix Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.